

Disclosures and Conflict of Interest (COI) Mitigation

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: J. Kim Penberthy, PhD; David Penberthy, MD; Limaya Atembina, MD ; Ankush Bhatia, MD; Thomas Griever, MD; Caleb Lauber, MD; Kurt Ottel, MD; David Gruber, MD; Benjamin Parsons, MD; Christopher Fletcher, MD; Nataliya Uboha, MD; Ryan Mattison, MD; Teresa Miller, MS, RDN, LDN; Ann Taylor, MD and the staffs of the Wisconsin Association of Hematology and Oncology, and Physicians' Education Resource®, LLC

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Shareholder	Other
Thomas Griever, DO, MBA					
Sailaja Kamaraju, MD, MS					Institutional PI for Phase 1 clinical trial-ongoing with VMO Oncology
Lee Wilke, MD					Founder and Minority stock owner with Elucent Medical, PI of clinical trial; no salary support; only support to the institution from Perimeter Medical
Tracy Kelly, MD					
William Gradishar, MD					
Malinda West, MD, MS					
Kari Wisinski, MD	Context Therapeutics-relationship ended. Pfizer, Novartis,	Novartis, Sanofi, Pfizer, and Loxo @Lilly-relationships ended. Stemline Therapeutics, Gilead and AstraZeneca			Site PI of clinical trial-AstraZeneca, Pfizer, Novartis, Genentech/Roche, Sanofi, Context Therapeutics, Zymeworks, Seagen, Relay and Puma
Lubna Chaudhary, MD					Advisory Board for Gilead Oncology, Novartis, and AstraZeneca (relationships all ended). Drug only funding for IIT from Regeneron Pharmaceuticals

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.